Welcome to NDF Research
  • Introducing NDF
  • About us
    • About our Senior Analyst
    • Disclaimer relating to research and web content
    • Financial Services Guide and General Advice Warning
  • What we do
    • The Rise of the New Analysts
    • MiFID II
  • Our sector
    • ASX-Listed Life Science companies we watch >
      • ASX-listed Life Science companies, >$200m
      • ASX-listed Life Science companies, $100-200m
    • About Australia and Australians
    • Australia and the Life Sciences
    • Life Sciences in New Zealand >
      • Building the New Zealand Life Sciences sector
    • A tour of Life Sciences Down Under
    • Australia's global competitiveness in Life Sciences >
      • Australia's Life Sciences Innovation Rating
      • Australia's Life Sciences clusters
      • Australia's World-Class Universities
      • Australia's Nobel Laureates
      • Australia's public policy support for Life Sciences
      • Australia's support for women in Life Sciences
    • The Coming Boom in Australian Life Sciences >
      • Welcome to Australia's Life Sciences Boom
    • Key organisations in the Life Science sector in Australia and New Zealand
    • Notable people in the Life Sciences sector in Australia and New Zealand >
      • Great CEOs
      • 2017 Red Hat Award Winners
      • 2018 Red Hat Award Winners
      • 2019 Red Hat Award Winners
    • The NDF Life Sciences Index >
      • 2016-2017 Year in Review
  • Our clients
  • Contact us
    • linkedin
    • Twitter
    • NDF Research Youtube Channel
  • Latest research
    • Comprehensive update reports
    • Shorter update reports
    • Initiation reports >
      • Admedus
      • Invion
    • Media and interviews
    • Presentations
    • Previous research and media, 2003-2015
    • A Brief History of the Life Sciences in Australia
    • In our library
    • Intellectual property >
      • Australian PCT patent applications
      • New Zealand PCT patent applications
      • PCT patent applications, last twelve months >
        • 2017 PCT patent applications
        • 2016 PCT patent applications
        • 2015 PCT patent applications
        • 2014 PCT patent applications
        • 2013 PCT patent applications
      • US patents >
        • 2017 US patents
        • 2016 US patents
        • 2015 US patents
        • 2014 US patents
    • Publications
    • Glossary
    • Global Life Science companies to watch
  • Blog
US patents related to the Life Sciences sector in Australia and New Zealand and granted in 2014
Compiled by Stuart Roberts, Senior Analyst, stuart@ndfresearch.com, +61 447 247 909 (3 October 2017)

The US Patent Office issues new patents every Tuesday. Australian assignees generally get two or three healthcare and biotech-related patents a week while New Zealand assignees get one every three or four weeks.

Australian grants

Here are the 137 US patents relevant to Australia's Life Sciences sector that were granted in 2014, for an issuance rate of 2.6 per week:
  • US Patent 8,921,414, Spiroketals, EcoBiotics Ltd, 30 December 2014
  • US Patent 8,921,374, Itraconazole compositions and dosage forms, and methods of using the same, Mayne Pharma (ASX: MYC), 30 December 2014​
  • US Patent 8,921,309, Lipopeptide compounds and their use, Uniquest Pty Ltd, 30 December 2014​
  • US Patent 8,921,306, Nociceptin mimetics, University of Queensland, 30 December 2014​
  • US Patent 8,920,851, Treatment of neurodegenerative diseases, Velacor Therapeutics, 30 December 2014​
  • US Patent 8,920,806, Method of modulating inflammatory response by downregulation of activin, Paranta Biosciences, 30 December 2014​
  • US Patent 8,920,803, Immunotherapeutic method involving CD123 (IL-3R.alpha.) antibodies and immunostimulating complex, CSL Ltd (ASX: CSL) , 30 December 2014​
  • US Patent 8,916,523, VIP fragments and methods of use, Vectus Biosystems (ASX: VBS), 23 December 2014​
  • US Patent 8,916,166, Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease, ​Oral Health CRC, 23 December 2014​
  • US Patent 8,912,225, VEGF inhibition, PharmAust (ASX: PAA), 16 December 2014​
  • US Patent 8,911,997, ​Mammalian cell culture medium, Queensland University of Technology, 16 December 2014​
  • US Patent 8,911,745, Immunology treatment for biofilms, Oral Health CRC, 16 December 2014​
  • US Patent 8,906,919, Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers, Ozteo Pty Ltd, 9 December 2014​
  • US Patent 8,906,912, Anxiolytic compounds, Bionomics (ASX: BNO), 9 December 2014​
  • US Patent 8,906,279, Humanized antibodies with anti-tumor activity, Teva Pharmaceuticals Australia, 2 December 2014​
  • US Patent 8,895,698, Binding partners of antibodies specific for dendritic cell antigens, Mater Hospital Brisbane, 25 November 2014​
  • US Patent 8,895,019, Biofilm treatment, ​Oral Health CRC, 25 November 2014​
  • US Patent 8,889,695, Quinazolinone compounds, Prana Biotechnology (ASX: PBT), 18 November 2014​
  • US Patent 8,883,015, Patch production, University of Queensland, 11 November 2014​
  • US Patent 8,877,727, Delivery of dsRNA to arthropods, Commonwealth Scientific and Industrial Research Organisation, 4 November 2014​
  • US Patent 8,877,243, Cross-linked polysaccharide composition,  Ultraceuticals, 4 November 2014​
  • US Patent 8,871,709, Synthetic chimeric proteins comprising epidermal growth factor and vitronectin, Queensland University of Technology, 28 October 2014
  • US Patent 8,871,272, Layered nanoparticles, ​Australian Nuclear Science & Technology Organisation, 28 October 2014​
  • US Patent 8,871,272, Probiotic storage and delivery, Commonwealth Scientific and Industrial Research Organisation, 28 October 2014​
  • US Patent 8,871,213, Prevention, treatment and diagnosis of P. gingivalis infection, Oral Health CRC, 28 October 2014​
  • US Patent 8,865,736, Antibacterial agents, Biota, 21 October 2014​
  • US Patent 8,859,627, Anti-microbial composition, Wild Child, 14 October 2014​
  • US Patent 8,858,951, Compositions for eliciting an immune response, University of Queensland, 14 October 2014​
  • US Patent 8,858,939, Ectopic pregnancy treatment, Monash University, 14 October 2014​
  • US Patent 8,252,641, Polymer microgel beads and preparative method thereof, University of Sydney, 7 October 2014​
  • ​US Patent 8,846,026, Composition comprising immunogenic microparticles, PX BioSolutions, 30 September 2014​
  • US Patent 8,841,420, Synthetic peptide constructs for the diagnosis and treatment of periodontis associated with Porphyromonas gingivalis, University of Melbourne, 23 September 2014​
  • US Patent 8,841,351, Polymeric topical compositions, Stiefel Research Australia, 23 September 2014​
  • US Patent 8,841,342, Carrier, Vital Health Sciences (Simon West), 23 September 2014​
  • US Patent 8,841,254, Method for treatment of anxiety, Florey Institute of Neuroscience and Mental Health, 23 September 2014​
  • US Patent 8,835,629,  Anti-cancer agents, Walter and Eliza Hall Institute, 16 September 2014​
  • US Patent 8,835,609, Antigen binding sites to non-functional oligomeric P2X7 receptors and methods of use thereof, Biosceptre International, 16 September 2014​
  • US Patent 8,835,478, Treatment for cancer, PharmAust (ASX: PAA), 16 September 2014​
  • US Patent 8,834,872, Uses of antibodies, Antony Scammell, 16 September 2014​
  • US Patent 8,828,933, Mutant Tat proteins and uses thereof, Queensland Institute of Medical Research, 9 September 2014​
  • US Patent 8,828,435, Buccal delivery system, Lingual Consegna Pty Ltd, 9 September 2014​
  • US Patent 8,828,409, Vaccine comprising recombinant CLPP protein of Streptococcus pneumoniae, ​Adelaide Research & Innovation with Sungkyunkwan University (Korea), 9 September 2014​
  • US Patent 8,822,644, Method of treating cancer comprising a VEGF-B antagonist, CSL Ltd (ASX: CSL), 2 September 2014​
  • US Patent 8,822,509, Pain-relieving compositions and uses therefor, University of Queensland, 2 September 2014​
  • US Patent 8,822,416, Topical analgesic composition, Animal Ethics Pty Ltd, 2 September 2014​
  • US Patent 8,822,409, Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith, Phylogica (ASX: PYC), 2 September 2014​
  • US Patent 8,815,936, Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders, NAD Life, 26 August 2014​
  • US Patent 8,815,298, Therapeutic composition comprising honey or a honey derivative, Medihoney Pty Ltd, 26 August 2014​
  • US Patent 8,815,291, Particles comprising a releasable dopant therein, Australian Nuclear Science & Technology Organisation, 26 August 2014​
  • US Patent 8,809,386, Use of dynamin ring stabilizers, Children's Medical Research Institute with MassGeneral (US), 19 August 2014​
  • US Patent 8,809,301, Surgical hydrogel, Adelaide Research & Innovation with Robinson Squidgel Ltd and (NZ) and University of Otago (NZ), 19 August 2014​
  • US Patent 8,808,751, Methods for the preparation of biologically active compounds in nanoparticulate form, iCeutica, 19 August 2014​
  • US Patent 8,808,716, Topical foam composition, Stiefel Research Australia, 19 August 2014​
  • US Patent 8,808,706, Arthrospira-based compositions and uses thereof, Biovite Australia, 19 August 2014​
  • US Patent 8,808,692, Compositions comprising immunoreactive reagents and saponins, and methods of use thereof,  CSL Ltd (ASX: CSL) , 19 August 2014
  • US Patent 8,807,861, Spreading implement, Acrux (ASX: ACR), 19 August 2014​
  • US Patent 8,802,840, Bicyclic nucleosides and nucleotides as therapeutic agents, Biota, 12 August 2014​
  • US Patent 8,802,634, CD40-L inhibitory peptides, Phylogica (ASX: PYC), 12 August 2014​
  • US Patent 8,802,625, Methods for promoting organ development, Kintan Pty Ltd, 12 August 2014​
  • US Patent 8,802,408, Process for preparing nutritional, therapeutic or organoleptic products from crude glycerol, Bio Processing Australia, 12 August 2014​
  • US Patent 8,802,135, Delivery system for remote treatment of an animal, Smartvet Pty Ltd, 12 August 2014​
  • US Patent 8,802,116, Poloxamer emulsion preparations, Novasel Pty Ltd (Steen Jorsal), 12 August 2014​
  • US Patent 8,796,273, Compound for the treatment of enteroviruses, Biota, 5 August 2014​
  • US Patent 8,796,225, Regulation of immune responses by modulation of the function of antigen presenting cells, Invion (ASX: IVX), 5 August 2014​
  • US Patent 8,790,909, Strains of Helicobacter pylori and uses thereof, Ondek, 29 July 2014​
  • US Patent 8,790,889, Neuronal stimulation, University of Queensland, 29 July 2014​
  • US Patent 8,785,478, Viral polymerase inhibitors, Biota, 22 July 2014​
  • US Patent 8,785,140, CD4+ CD25+ T-cells activated to a specific antigen, University of New South Wales, 22 July 2014​
  • US Patent 8,784,878, Transdermal delivery rate control using amorphous pharmaceutical compositions,  Acrux (ASX: ACR), 22 July 2014
  • US Patent 8,784,831, P. gingivalis antigenic composition, CSL Ltd (ASX: CSL) with University of Melbourne, 22 July 2014​
  • US Patent 8,779,107, Composition for targeting dendritic cells, Lipotek with GSK (UK), 15 July 2014​
  • US Patent 8,778,400, Nanoparticle-stabilized capsule formulation for treatment of inflammation, University of South Australia, 15 July 2014​
  • US Patent 8,778,300, Method of forming an injectable radioactive composition of a carbon encapsulated radioactive particulate, Australian National University, 15 July 2014​
  • US Patent 8,772,013, Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells, EnGeneIC, 8 July 2014​
  • US Patent 8,771,764, Composition and method for improving vascular health, Commonwealth Scientific and Industrial Research Organisation with the Malaysian Palm Oil Board (Malaysia), 8 July 2014​
  • US Patent 8,771,739, Pharmaceutical compositions for poorly soluble drugs, Mayne Pharma (ASX: MYC), 8 July 2014​
  • US Patent 8,771,701, Compositions for immunotherapy and uses thereof, Burnet Institute, 8 July 2014​
  • US Patent 8,765,812, Therapeutic compounds, Fibrotech Therapeutics, 1 July 2014​
  • US Patent 8,765,700, Topical administrations of antisense compounds to VLA-4 for the treatment of respiratory conditions, Antisense Therapeutics (ASX: ANP), 1 July 2014​
  • US Patent 8,765,677, Omega conotoxin peptides, University of Queensland with University of Sydney, 1 July 2014​
  • US Patent 8,765,183, Polymer microgel beads, University of Sydney, 1 July 2014​
  • US Patent 8,765,163, Biocompatible material and uses thereof, University of Sydney, 1 July 2014
  • US Patent 8,765,144, Antigenic complex for the diagnosis and treatment of Porphyromonas gingivalis infection, University of Melbourne, 1 July 2014​
  • US Patent 8,759,286, Pharmaceutical compositions comprising a VEGF-D polypeptide, ​Opthea (ASX: OPT), 24 June 2014​
  • US Patent 8,758,728, Foamable suspension gel, Stiefel Research Australia, 24 June 2014​
  • US Patent 8,748,406, Preventive for adhesion following abdominal surgery, Cellmid (ASX: CDY), 10 June 2014​
  • US Patent 8,747,830, Wound repair composition and method, Queensland University of Technology, 10 June 2014
  • US Patent 8,741,970, Composition and method for the enhancement of the efficacy of drugs, Alchemia (ASX: ACL), 3 June 2014​
  • US Patent 8,741,296, Adenocarcinoma specific antibody SAM-6, and uses thereof, Patrys (ASX: PAB), 3 June 2014​
  • US Patent 8,735,566, Bacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells, EnGeneIC, 27 May 2014​
  • US Patent 8,735,173, Multiplex screening for lysosomal storage disorders (LSDS),  Women's and Children's Hospital, Adelaide, 27 May 2014
  • US Patent 8,729,020, Methods for the treatment of aortic fibrosis with VIP fragments, Vectus Biosystems (ASX: VBS), 20 May 2014​
  • US Patent 8,728,512, Treatment and composition for wound healing, Professor Christopher Jackson, 20 May 2014​
  • US Patent 8,722,675, Method of treatment or prophylaxis, Spinifex Pharmaceuticals, 13 May 2014​
  • US Patent 8,722,634, Use of compounds extracted from Momordica charantia L. in the manufacture of medicaments for prevention and treatment of diabetes and obesity,  Garvan Institute of Medical Research with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (China), 13 May 2014​
  • US Patent 8,722,036, Methods for treating malignancies using coxsackieviruses, Viralytics (ASX: VLA), 13 May 2014​
  • US Patent 8,716,335, Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors, Bionomics (ASX: BNO), 6 May 2014
    US Patent 8,716,222, Methods and compositions for promoting organ development, Kintan Pty Ltd, 6 May 2014​
  • US Patent 8,715,724, Tabletting process, Mayne Pharma (ASX: MYC), 6 May 2014​
  • US Patent 8,710,015, Tropoelastin derivatives, University of Sydney, 29 April 2014​
  • US Patent 8,709,486, Administrable compositions, University of Sydney, 29 April 2014​
  • US Patent 8,709,425, Antibodies to non-functional P2X7 receptor, Biosceptre International, 29 April 2014​
  • US Patent 8,703,147, Methods and compositions for treating and preventing malaria, Walter and Eliza Hall Institute, 22 April 2014
  • US Patent 8,703,116, Modified macromolecule, Starpharma (ASX: SPL), 22 April 2014
  • US Patent 8,697,702, Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate, Medvet Science Pty Ltd with Novartis (Switerland) , 15 April 2014​
  • US Patent 8,697,678, Anaesthetic formulation, Drawbridge Pharmaceuticals, 15 April 2014​
  • US Patent 8,697,145, Substances having body mass redistribution properties, Horizon Science Pty Ltd (David Kannar and Barry Kitchen), 15 April 2014​
  • US Patent 8,691,967, Multiple promoter expression cassettes for simultaneous delivery of RNAi agents, Benitec (ASX: BLT), 8 April 2014​
  • US Patent 8,691,963, Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells, EnGeneIC, 8 April 2014​
  • US Patent 8,691,765, Metallothionein based neuronal therapeutic and therapeutic methods, University of Tasmania, 8 April 2014​
  • US Patent 8,686,110, Therapeutic pro-apoptotic BH3-like molecules and methods for generating and/or selecting the same, Walter and Eliza Hall Institute, 1 April 2014​
  • US Patent 8,685,473, Pawpaw and/or peach derived composition, Phoenix Eagle, 1 April 2014​
  • US Patent 8,680,141, Spiroketals, EcoBiotics, 25 March 2014​
  • US Patent 8,680,135, Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors, Bionomics (ASX: BNO), 25 March 2014
  • US Patent 8,673,872, Method of modulation of expression of epidermal growth factor receptor(EGFR) involving miRNA, University of Western Australia, 18 March 2014​
  • US Patent 8,673,586, Compounds that interact with kinases, Alchemia (ASX: ACL), 18 March 2014​
  • US Patent 8,673,367, Nano silver-zinc oxide composition, Polymers CRC, 18 March 2014​
  • US Patent 8,673,363, Dental mineralization, University of Melbourne, 18 March 2014​
  • US Patent 8,673,361, Cytokine modulating composition, Cambridge Scientific Pty Ltd (Maud Eijkenboom)​, 18 March 2014​
  • US Patent 8,673,305, Methods of treatment with antibodies against the extracellular loops of C5aR, G2 Therapies, 18 March 2014​
  • US Patent 8,669,280, Antiviral compounds and methods, Biotron (ASX: BIT), 11 March 2014​
  • US Patent 8,669,101, Bacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells, EnGeneIC, 11 March 2014​
  • US Patent 8,653,236, Therapeutic agents, Inter-K Pty Ltd, 18 February 2014​
  • US Patent 8,652,511, Transdermal delivery patch, Phosphagenics (ASX: POH), 18 February 2014​
  • US Patent 8,652,473, Antibodies to EGF receptor epitope peptides and uses thereof, Commonwealth Scientific and Industrial Research Organization with the Ludwig Institute for Cancer Research (US) and Massachusetts Institute of Technology (US), 18 February 2014​
  • US Patent 8,642,731, Porphyromonas gingivalis polypeptides and nucleotides, CSL Ltd (ASX: CSL) with University of Melbourne, 4 February 2014
  • US Patent 8,642,631, Methods of treating mammals with eustachian tube dysfunctions,  University of Melbourne, 4 February 2014​
  • US Patent 8,637,262, Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof, Opthea (ASX: OPT), 28 January 2014​
  • US Patent 8,637,051, Compositions and methods for treatment of mucosal infections, Hunter Immunology, 28 January 2014​
  • US Patent 8,637,025, Composition and method for the treatment and prevention of enteric bacterial infections, Immuron (ASX: IMC), 28 January 2014​
  • US Patent 8,637,016, EphA3 antibodies for the treatment of solid tumors, Monash University with KaloBios Pharmaceuticals (US) and the Ludwig Institute for Cancer Research (US , 28 January 2014​
  • US Patent 8,629,318, Transgenic animals for analyzing CYP3A4 cytochrome P450 gene regulation, University of Sydney, 14 January 2014​
  • US Patent 8,629,241, Alpha helical mimics, their uses and methods for their production, University of Queensland, 14 January 2014​
  • US Patent 8,628,761, Biodegradable polyurethane/urea compositions, Polynovo (ASX: PNV), 14 January 2014​
  • US Patent 8,624,025, Antiviral agents, Biota, 7 January 2014​
  • US Patent 8,623,836, Modulation of growth hormone receptor expression and insulin-like growth factor expression, Antisense Therapeutics and Isis Pharmaceuticals, 7 January 2014
  • US Patent 8,623,354, Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment, Alchemia (ASX: ACL), 7 January 2014​

New Zealand applications

Here are the 15 US patents relevant to New Zealand's Life Sciences sector that were granted in 2014, for an issuance rate of 0.2 applications per week:
  • US Patent 8,889,636, Anti-microbial compositions, Biotelliga,  18 November 2014
  • US Patent 8,877,465, Production of ultrapure EPA and polar lipids from largely heterotrophic culture, Photonz,  4 November 2014
  • US Patent 8,835,397, Macrocyclic lactone tablet formulation, Bayer New Zealand,  16 September 2014
  • US Patent 8,821,921, Vitamin D3 for the transdermal treatment of pain and inflammation, Anzamed International (Dr John Lyftogt),  2 September 2014
  • US Patent 8,809,301, Surgical hydrogel, Robinson Squidgel Ltd with University of Otago and Adelaide Research & Innovation (Australia), 19 August 2014​
  • US Patent 8,791,117, Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals, Neuren Pharmaceuticals (ASX: NEU),  29 July 2014
  • US Patent 8,784,795, Methods for determining personalized treatment compositions for prostate cancer and breast cancer, Caldera Health,  22 July 2014
  • US Patent 8,758,781, Tissue scaffolds derived from forestomach extracellular matrix, Aroa Biosurgery,  24 June 2014
  • US Patent 8,709,448, Anti-infective agents and uses thereof, Innate Immunotherapeutics (ASX: IIL),  29 April 2014
  • US Patent 8,703,699, Lactoferrin, Auckland UniServices (University of Auckland),  22 April 2014
  • US Patent 8,679,527, Antimicrobial compositions, Manuka Health,  25 March 2014
  • US Patent 8,669,084, Functional lipid constructs, Kode Biotech,  11 March 2014
  • US Patent 8,637,567, Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid, Neuren Pharmaceuticals (ASX: NEU),  28 January 2014
  • US Patent 8,637,473, Synthetic membrane anchors,  Kode Biotech,  28 January 2014
  • US Patent 8,633,248, Parenteral selenomethionine for production of selenium-rich foods, AgResearch Ltd,  21 January 2014

Copyright © 2017 NDF Research
Proudly powered by Weebly
  • Introducing NDF
  • About us
    • About our Senior Analyst
    • Disclaimer relating to research and web content
    • Financial Services Guide and General Advice Warning
  • What we do
    • The Rise of the New Analysts
    • MiFID II
  • Our sector
    • ASX-Listed Life Science companies we watch >
      • ASX-listed Life Science companies, >$200m
      • ASX-listed Life Science companies, $100-200m
    • About Australia and Australians
    • Australia and the Life Sciences
    • Life Sciences in New Zealand >
      • Building the New Zealand Life Sciences sector
    • A tour of Life Sciences Down Under
    • Australia's global competitiveness in Life Sciences >
      • Australia's Life Sciences Innovation Rating
      • Australia's Life Sciences clusters
      • Australia's World-Class Universities
      • Australia's Nobel Laureates
      • Australia's public policy support for Life Sciences
      • Australia's support for women in Life Sciences
    • The Coming Boom in Australian Life Sciences >
      • Welcome to Australia's Life Sciences Boom
    • Key organisations in the Life Science sector in Australia and New Zealand
    • Notable people in the Life Sciences sector in Australia and New Zealand >
      • Great CEOs
      • 2017 Red Hat Award Winners
      • 2018 Red Hat Award Winners
      • 2019 Red Hat Award Winners
    • The NDF Life Sciences Index >
      • 2016-2017 Year in Review
  • Our clients
  • Contact us
    • linkedin
    • Twitter
    • NDF Research Youtube Channel
  • Latest research
    • Comprehensive update reports
    • Shorter update reports
    • Initiation reports >
      • Admedus
      • Invion
    • Media and interviews
    • Presentations
    • Previous research and media, 2003-2015
    • A Brief History of the Life Sciences in Australia
    • In our library
    • Intellectual property >
      • Australian PCT patent applications
      • New Zealand PCT patent applications
      • PCT patent applications, last twelve months >
        • 2017 PCT patent applications
        • 2016 PCT patent applications
        • 2015 PCT patent applications
        • 2014 PCT patent applications
        • 2013 PCT patent applications
      • US patents >
        • 2017 US patents
        • 2016 US patents
        • 2015 US patents
        • 2014 US patents
    • Publications
    • Glossary
    • Global Life Science companies to watch
  • Blog